EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 170 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $15,690 | +74.3% | 3,000 | +849.4% | 0.00% | – |
| Q4 2022 | $9,000 | -55.0% | 316 | -57.6% | 0.00% | – |
| Q3 2022 | $20,000 | -4.8% | 745 | +61.3% | 0.00% | – |
| Q2 2022 | $21,000 | +75.0% | 462 | +92.5% | 0.00% | – |
| Q1 2022 | $12,000 | -98.5% | 240 | -98.3% | 0.00% | -100.0% |
| Q3 2019 | $816,000 | +92.5% | 14,423 | +89.2% | 0.00% | +100.0% |
| Q2 2019 | $424,000 | +0.5% | 7,622 | -8.8% | 0.00% | 0.0% |
| Q1 2019 | $422,000 | +25.2% | 8,360 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $337,000 | +200.9% | 8,360 | +415.4% | 0.00% | +100.0% |
| Q3 2018 | $112,000 | -74.4% | 1,622 | -80.5% | 0.00% | -50.0% |
| Q1 2018 | $438,000 | +0.2% | 8,308 | +1.6% | 0.00% | 0.0% |
| Q4 2017 | $437,000 | -66.4% | 8,180 | -50.4% | 0.00% | -50.0% |
| Q2 2017 | $1,300,000 | – | 16,486 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
| Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
| Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
| Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
| Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
| U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
| GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
| Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |